• Waldenström Macroglobulinemia
  • Melanoma
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Childhood Cancers
  • Gastric Cancer
  • Gynecologic Cancer
  • Head & Neck Cancer
  • Immunotherapy
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma Cancer
  • Mesothelioma
  • MPN
  • MDS
  • Myeloma
  • Prostate Cancer
  • Rare Cancers
  • Sarcoma
  • Skin Cancer
  • Testicular Cancer
  • Thyroid Cancer

Novel Hormone Therapy Combination Shown to Prolong Survival

Article

A phase 3 randomized trial of two hormone therapies showed that in some postmenopausal women with hormone-positive metastatic breast cancer, the combo improves survival.

A phase 3 randomized trial of two hormone therapies, anastrozole and Faslodex (fulvestrant), showed that in some postmenopausal women with hormone-positive metastatic breast cancer, the combo improves survival.

Both are approved for women with hormone-positive metastatic breast cancer. Faslodex is used when the cancer has stopped responding to other hormonal therapies. Anastrozole is an aromatase inhibitor also approved to prevent breast cancer from recurring in women with early-stage disease.

The trial, which was presented a breast cancer conference in December, included 707 women who had not been previously treated for metastatic cancer. The combination improved median survival from 41.3 months to 47.7 months.

Related Videos
Sue Friedman in an interview with CURE
Catrina Crutcher in an interview with CURE